Breast Cancer Research and Treatment

, Volume 67, Issue 1, pp 61–70

Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype

  • Karin Milde-Langosch
  • Ana-Maria Bamberger
  • Gabriele Rieck
  • Bianca Kelp
  • Thomas Löning
Conference Report

Abstract

In order to study the role of the p16INK4A(MTS1/CDKN2a) tumor suppressor in breast cancer, we analyzed p16 protein expression in 60 breast cancer samples which were also analyzed for expression of Rb, Ki67, HER2/neu, and estrogen and progesterone receptors (ER, PR). P16 expression was investigated by two methods: western blotting (WB) followed by densitometry, and immunohistochemistry (IHC). The Rb status was studied by western blotting, and expression of Ki67, HER2/neu, ER, and PR was analyzed immunohistochemically. P16-negative results were found in 18% of the carcinomas by WB, but in only one case by IHC and were not associated with established prognostic parameters. In contrast, p16 overexpression which was detected by WB and IHC in 15% and 25% of the tumors, respectively, was significantly associated with unfavorable prognostic indicators. High p16 expression as detected by both methods correlated significantly with high grading and a negative estrogen receptor status. In addition, a significant association of p16 staining with inverse progesterone receptor status and high Ki67 expression was found with IHC. No correlation of p16 expression with clinical stage, HER2/neu immunostaining, Rb expression or Rb phosphorylation was found. Comparison of western blot results and immunohistochemistry suggests that both nuclear and cytoplasmic immunoreactivity in tumor cells is specific and due to p16 expression. We conclude that high p16 reactivity (both nuclear and cytoplasmic) is indicative of a more undifferentiated, malignant phenotype in mammary carcinomas.

breast cancer immunohistochemistry p16 Rb western blots 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177, 1998Google Scholar
  2. 2.
    Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J, Preudhomme C, Peyrat JP: Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 72: 351-353, 1995Google Scholar
  3. 3.
    Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA: Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 72: 964-967, 1995Google Scholar
  4. 4.
    Musgrove EA, Lee CSL, Cornish AL, Swarbrick A, Sutherland RL: Antiprogest in inhibition of cell cycle progression in T47-D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11: 54-66, 1997Google Scholar
  5. 5.
    Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM: Preferential loss of expression of p16 (INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 2: 1993-1998, 1996Google Scholar
  6. 6.
    Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995Google Scholar
  7. 7.
    Van Zee KJ, Calvano JE, Bisogna M: Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 16: 2723-2727, 1998Google Scholar
  8. 8.
    Kelley MJ, Otterson GA, Kaye FJ, Popescu NC, Johnson BE, Dipaolo JA: CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 63: 226-230, 1995Google Scholar
  9. 9.
    Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histological parameters. Int J Cancer 79: 71-75, 1998Google Scholar
  10. 10.
    Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558, 1999Google Scholar
  11. 11.
    Milde-Langosch K, Ocon E, Becker G, Löning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79: 61-65, 1998Google Scholar
  12. 12.
    Milde-Langosch K, Riethdorf L, Bamberger A-M, Löning T: P16/MTS1 and pRb expression in endometrial carcinomas. Virchows Arch 434: 23-28, 1999Google Scholar
  13. 13.
    Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, Wallwiener D, Sinn H-P: Aberrant cytoplasmic expression of the p16 prote in in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668, 1998Google Scholar
  14. 14.
    Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266, 1992Google Scholar
  15. 15.
    Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JFR, Sutherland RL: INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 6: 2777-2787, 2000Google Scholar
  16. 16.
    Geradts J, Wilson PA: High frequency of aberrant p16 INK4A expression in human breast cancer. Am J Pathol 149: 15-20, 1996Google Scholar
  17. 17.
    Kaneko S, Nishioka J, Tanaka M, Nakashima K, Nobori T: Transcriptional regulation of the CDK inhibitor p16INK4a gene by a novel pRb-associated repressor, RBAR1. Biochem Mol Biol Int 47: 205-215, 1999Google Scholar
  18. 18.
    Huschtscha LI, Noble JR, Neumann AA, Moy EL, Barry P, Melki JR, Clark SJ, Redell RR: Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 58: 3508-3512, 1998Google Scholar
  19. 19.
    Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K: Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Karin Milde-Langosch
    • 1
  • Ana-Maria Bamberger
    • 1
  • Gabriele Rieck
    • 1
  • Bianca Kelp
    • 1
  • Thomas Löning
    • 1
  1. 1.Institute of Pathology, Department of GynecopathologyUniversity Hospital EppendorfHamburgGermany

Personalised recommendations